Oxygen Biotherapeutics and U.S. Navy Expand Collaboration with Cooperative Research & Development Agreement to Study Oxycyte® for Treatment of Hemorrhagic Shock
08:00 EDT 2 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a development stage
biomedical company focused on developing oxygen-carrying intravenous and
topical products, announced today that it has entered into a Cooperative
Research and Deve...
Other Sources for this Article
Oxygen Biotherapeutics, Inc.
Ellen Corliss, 919-855-2112
Senior
Vice President
Corporate Communications
& Investor Relations
More From BioPortfolio on "Oxygen Biotherapeutics and U.S. Navy Expand Collaboration with Cooperative Research & Development Agreement to Study Oxycyte® for Treatment of Hemorrhagic Shock"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
